It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Fusion genes are hallmarks of various cancer types and important determinants for diagnosis, prognosis and treatment. Fusion gene partner choice and breakpoint-position promiscuity restricts diagnostic detection, even for known and recurrent configurations. Here, we develop FUDGE (FUsion Detection from Gene Enrichment) to accurately and impartially identify fusions. FUDGE couples target-selected and strand-specific CRISPR-Cas9 activity for fusion gene driver enrichment — without prior knowledge of fusion partner or breakpoint-location — to long read nanopore sequencing with the bioinformatics pipeline NanoFG. FUDGE has flexible target-loci choices and enables multiplexed enrichment for simultaneous analysis of several genes in multiple samples in one sequencing run. We observe on-average 665 fold breakpoint-site enrichment and identify nucleotide resolution fusion breakpoints within 2 days. The assay identifies cancer cell line and tumor sample fusions irrespective of partner gene or breakpoint-position. FUDGE is a rapid and versatile fusion detection assay for diagnostic pan-cancer fusion detection.
Fusion genes are a hallmarks of cancer, though breakpoint-position promiscuity restricts diagnostic detection. Here, the authors present FUDGE, a CRISPR-Cas9-based enrichment strategy for nanopore sequencing to identify target fusions irrespective of genomic breakpoint or fusion partner.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Renkens Ivo 2 ; Westera Liset 3 ; Verbeek, Tamara 2 ; Valle-Inclan Jose Espejo 4 ; González, Rocio Chamorro 5
; Henssen, Anton G 6
; van Roosmalen Markus J 7 ; Stam, Ronald W 8 ; Voest, Emile E 9
; Kloosterman Wigard P 2
; van Haaften Gijs 2
; Monroe, Glen R 2
1 University Medical Center Utrecht and Utrecht University, Department of Genetics, Center for Molecular Medicine, Utrecht, Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352); Plesmanlaan, Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands (GRID:grid.7692.a); Oncode Institute, Utrecht, Netherlands (GRID:grid.499559.d)
2 University Medical Center Utrecht and Utrecht University, Department of Genetics, Center for Molecular Medicine, Utrecht, Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
3 Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands (GRID:grid.487647.e); Dutch Childhood Oncology Group (DCOG), Den Haag, Netherlands (GRID:grid.476268.9) (ISNI:0000 0004 0395 3851)
4 University Medical Center Utrecht and Utrecht University, Department of Genetics, Center for Molecular Medicine, Utrecht, Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352); Oncode Institute, Utrecht, Netherlands (GRID:grid.499559.d)
5 Charité-Universitätsmedizin Berlin, Department of Pediatric Oncology/Hematology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany (GRID:grid.419491.0) (ISNI:0000 0001 1014 0849)
6 Charité-Universitätsmedizin Berlin, Department of Pediatric Oncology/Hematology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany (GRID:grid.419491.0) (ISNI:0000 0001 1014 0849); German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Berlin Institute of Health, Berlin, Germany (GRID:grid.484013.a)
7 Oncode Institute, Utrecht, Netherlands (GRID:grid.499559.d); Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands (GRID:grid.487647.e)
8 Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands (GRID:grid.487647.e)
9 Plesmanlaan, Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands (GRID:grid.487647.e); Oncode Institute, Utrecht, Netherlands (GRID:grid.499559.d)




